The Benefits and Risks of Cannabis and Cannabinoids in Treating Pain

Daniel J. Clauw M.D.
dclauw@umich.edu
Professor of Anesthesiology, Medicine (Rheumatology), and Psychiatry
Director, Chronic Pain and Fatigue, Research Center,
The University of Michigan
Disclosures

- **Consulting**
  - Pfizer, Forest, Eli Lilly, Pierre Fabre, Cypress Biosciences, Wyeth, UCB, AstraZeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, IMC, Zynerba, Sammumed, Aptinyx

- **Research support**
  - Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex

- One-time licensing fee paid to University of Michigan by Eli Lilly
How useful do you feel cannabinoids are for treating pain?

Worthless 10

0 Wonderful
Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: a methodological and political minefield

Winfried Häuser, Nanna B. Finnerup, R. Andrew Moore

Public interest in cannabis products for medical purposes has been widely advocated, with legalization for recreational and medical use in North America and some European countries. Legalization of cannabis-based medicines (CBMs) (medical cannabis, plant-based cannabinoids [tetrahydrocannabinol, cannabidiol, and combinations], and synthetic tetrahydrocannabinol analogues) has bypassed usual drug regulatory procedures. Systematic reviews with meta-analyses of randomised controlled trials (RCTs) with CBM for chronic pain conditions help determine “post hoc” whether the preconditions of drug agencies for approval were met and to guide physicians and patients.

A systematic review of systematic reviews on CBM highlighted the uncertainty about whether CBMs improve pain, with only low or very low quality evidence available. Individual systematic reviews generally avoided issues of trial quality, usually had some flaws, and included different drugs, doses, durations, conditions, and outcomes. Most reviews agreed that there was no, or no clinically relevant, effect.

In this issue of PAIN, Stockings et al. provide the most comprehensive systematic review with meta-analysis of RCTs and observational studies with CBM, including 47 RCTs with 4271 patients with chronic noncancer pain. Study duration ranged between 1 day and 26 weeks. The authors avoid some methodology flaws of some of the systematic reviews mentioned above. They included “gray” literature and used all studies providing data in quantitative analyses. Average pain intensity, 30% and 50% or more pain relief, emotional and physical function, side effects, and quality of life were all assessed.

There remains a methodological minefield, through which we need to step carefully. For example:

1. Most studies analysed are of low methodology quality.
2. Most studies included fewer than 50 patients per treatment arm. Small CBM studies are often the most positive.
3. Short-duration experimental studies (hours, a single day) were included, unhelpful in judging longer-term efficacy.
4. Lumping all chronic pain syndromes together does not help in managing individual patients, given the heterogeneity of chronic pain and its mechanisms. Even the importance of subgroup analyses is limited: cancer pain might have nociceptive and/or neuropathic components; neuropathic pain can have many dimensions, and drugs might be effective for some dimensions of neuropathic pain but not for others.
5. Whether heterogeneity of pain mechanisms is relevant for the efficacy of CBM, which are nonspecific centrally acting drugs, is, however, unknown.
6. Lumping together all CBMs, including experimental drugs unavailable for clinical use, limits the clinical relevance of combined results.
7. There is the risk of overestimating the effects of CBM for pain relief because of unpublished studies, for example, with nabilone for chronic neuropathic pain.
8. Long-term risk and severe but rare side effects are not captured in small, short-duration trials.

What can patients, clinicians, trialists, drug companies, and policy makers do? So the search continues, and that is the exciting part.
Benefits and Risks of Cannabinoids

- Definitions and Background
- Benefits of Cannabinoids
- Risks of Cannabinoids
- Role in Treating Chronic Pain
- Summary
Benefits and Risks of Cannabinoids

- Definitions and Background
- Benefits of Cannabinoids
- Risks of Cannabinoids
- Role in Treating Chronic Pain
- Summary
Definitions

- **Cannabis** – A genus of flowering plants with three different species: indica, sativa, and ruderalis
  - Can be bred to have low amounts of psychoactive compounds (e.g. THC) that are used to make hemp, or high amounts that are used for recreational/medicinal purposes
  - Sativex is an oral spray that is a cannabis extract

- **Cannabinoid** – Compounds that act at cannabinoid receptors
  - Endocannabinoids – endogenous ligands produced naturally that bind to CB1 and CB2 receptors
  - Phytocannabinoids – plant origin (cannabis/marijuana)
    - At least 80 different cannabinoids in cannabis
  - Synthetic cannabinoids

CB, cannabinoid receptor; THC, tetrahydrocannabinol
Endocannabinoid system - I

A set of receptors and their naturally occurring ligands and enzymes regulating control

- **Receptors** – G-coupled protein receptors (the most abundant in CNS in man) on presynaptic membrane of cells in peripheral and central nervous system
  - CB1 – Primarily in central nervous system (but not in medulla in man) these act primarily to inhibit release of neurotransmitters
  - CB2 – Largely found in periphery on immune and nerve cells (although some in CNS on microglia and DRG)
  - Other receptors can bind these ligands because there is activity in CB1/CB2 knockouts (TRPV1, GPR55)

CB, cannabinoid receptor; CNS, central nervous system, DRG, dorsal root ganglion
Endocannabinoid system - II

**Ligands** – Endocannabinoids are eicosanoid lipid messengers that are the physiological ligands for the cannabinoid receptors:
- ananamide (N-arachidonolethanolamide, AEA)
- 2-arachidonoylglycerol (2-AG)
- PEA, virodamine, OAE

**Enzymes** that synthesize and degrade the lipids endocannabinoids, such as fatty acid amide hydroxylase or monoacylglycerol lipase
- Drugs being developed for pain that inhibit these enzymes

AEA, arachidonolethanolamine  PEA, palmitoylethanolamide; OAE, oleoylethanolamine
Endocannabinoid system

Endocannabinoid system - III

Some known functions of the endocannabinoid system in humans:

- **Memory** – Generally affect short term memory, may play adaptive role in extinction of old memories in hippocampus

- **Neurogenesis**

- **Appetite** – Act in hypothalamus to increase appetite, inversely related to leptin levels

- **Analgesia**

- **Immune function** – Generally inhibit immune function, generally mediated via CB2\(^1\) but some evidence CB1 might play role in T-cell responses. May be upregulation of CB2 receptors in some inflammatory disorders

- **Stress** – Help habituate/reduce HPA axis activity during repeated stress\(^2\)

CB, cannabinoid receptor; HPA, hypothalamic-pituitary-adrenal

CB, cannabinoid receptor
Cannabis-derived cannabinoids

More than 80 known, with different strains having different relative concentrations

- **THC** (Synthetic forms include Dronabinol, Marinol, Nabilone)
  - The primary psychoactive cannabinoid in cannabis, and its metabolites are those assayed for in drug tests
  - Although it binds relatively equally to both the CB1 and CB2 receptors, most of its effects are associated with CB1 activity in brain

CB, cannabinoid receptor; THC, Tetrahydrocannabinol
Cannabis-derived cannabinoids

**Cannabidiol (CBD)**

- Is not psychoactive and does not bind with any significant affinity to CB receptors, but yet has anticonvulsant and anti-inflammatory effects.
- Is actually thought to potentially protect against psychoactive effects of THC and hypothesized by some to be an effective anti-psychotic (although a recent Cochrane review concluded there was insufficient evidence of this).
- May act as an indirect antagonist of CB agonists – but it does not seem to reduce activity of THC.
- Also acts as 5HT1a agonist which might be responsible for potential analgesic, antidepressant effects.

5HT1a, 5-hydroxytriptamine 1A receptor; CB, cannabinoid receptor; THC, tetrahydrocannabinol

Clinical Effects of Cannabidiol

- Best established effects are in epilepsy, especially rare childhood forms such as Dravet Syndrome
  - GW Pharmaceuticals is seeking approval of CBD for treatment of Dravet syndrome and was granted fast track approval
- Neuroprotective effects are also being aggressively studied
- Seems to be generally very well tolerated
  - May lead to anxiety behaviors in animals although this is disputed

CBD, cannabidiol
Benefits and Risks of Cannabinoids

- Definitions and Background
- Benefits of Cannabinoids
- Risks of Cannabinoids
- Role in Treating Chronic Pain
- Summary
Potential Benefits of Cannabinoids

- **Antiemetic¹** – Marinol is FDA-approved (Schedule III) for use in post-chemotherapy nausea/vomiting
- **Anorexia** – Marinol is FDA-approved for this use in AIDS-induced anorexia in US
- **Anti-spasticity agent²**
- **Anticonvulsant³** – Focus on CBD effects
- **Neuroprotective**
  - Being studied in Alzheimer’s⁴ because preclinical models show CB1/2 activation leads to reduction in beta-amyloid
  - Retrospective study of patients admitted with severe TBI showed significant reduction in death in those who had a positive drug screen for THC⁵
- **Anti-tumor effects⁶**

AIDS, acquired immune deficiency syndrome; CB, cannabinoid receptor; CBD, cannabidiol; FDA, Food and Drug Administration; TBI, traumatic brain injury; THC, tetrahydrocannabinol

Benefits and Risks of Cannabinoids

- Definitions and Background
- Benefits of Cannabinoids
- Risks of Cannabinoids
- Role in Treating Chronic Pain
- Summary
**Risks of Cannabinoids**

- Almost all available data is from long term recreational users so we probably have good “worst case” data
- Partly related to route of administration
  - Smoking cannabis may lead to chronic bronchitis and potentially cancer of the mouth, throat, lung
  - This is likely reduced or eliminated with use of vaporizers or e-cigarettes
  - Oral administration causes less “likability” than inhalation or smoking and presumably no risk of bronchitis or cancer
  - *Individuals using cannabis for medicinal purposes should probably be using an oral formulation but dosing is problematic*
- The few deaths associated with cannabis are generally due to severe paranoia or tachycardia associated with overdose via oral administration

Long Term Risks of Cannabinoids

- Psychotic illnesses
  - It is now generally accepted that individuals who begin smoking cannabis prior to age 25 have 1.5 – 2.4X the rate of developing a psychotic illness.
  - This risk is modified by childhood trauma, family history of a psychotic illness, and perhaps genetic polymorphisms.

- Long term effects on memory and brain structure
  - Both neuropsychological testing, and functional and structural neuroimaging studies, have suggested that individuals who use cannabis recreationally beginning in adolescence have decreased cognitive performance.
  - These studies have significant methodological issues because of other common exposures (e.g. alcohol or other illicit drugs) and behavioral issues in these individuals.

References:
Risks of Cannabinoids

- Respiratory
- Dependence
  - Occurs in approximately 9% of individuals who use cannabis, but is about double in those who begin using in adolescence
  - This is lower than almost all other drugs of abuse (nicotine 32%, opioids 23%, alcohol 15%)
  - Highest risk in those with poor academic achievement, deviant behavior in childhood, poor parental relationships, family history of substance abuse
  - Physical addiction and withdrawal are much less common/severe than other drugs of abuse

Comparison of classification systems for the harms and risks of drug abuse in the development of the multi-category Nutt rational scale

Correlation between mean scores from the independent experts and the specialist addiction psychiatrists 1=heroin. 2=cocaine. 3=alcohol. 4=barbiturates. 5=amphetamine. 6=methadone. 7=benzodiazepines. 8=solvents. 9=buprenorphine. 10=tobacco. 11=ecstasy. 12=cannabis. 13=LSD. 14=steroids

Benefits and Risks of Cannabinoids

- Definitions and Background
- Benefits of Cannabinoids
- Risks of Cannabinoids
- Role in Treating Chronic Pain
- Summary
Preclinical models of pain

- Animal models of pain with CB1 agonists, CB2 agonists and mixed CB1/CB2 agonists.
- Because of CNS actions, compounds with CB1 activity cause more “off-target” side effects.
- THC reduces connectivity between limbic and sensory brain regions, and thus unpleasantness of pain (may be mechanism with nausea).
- Selective CB2 agonists (e.g., ajulemic acid) should have considerably less CNS effects.
- Good for nociceptive or inflammatory mechanisms of pain.
- Not good for pain of CNS origin.

References:

https://www.corbuspharma.com/pipeline/lenabasum
Mechanisms of analgesic action of cannabinoids

- In periphery, CB2 activation leads to fairly pronounced anti-inflammatory effect
  - May have less effect on nociceptive pain that is not of inflammatory origin

- In CNS, cannabis (presumably mainly via CB1 effects) has a dissociative effect of reducing connectivity between limbic and sensory brain regions and reduces the unpleasantness of pain

  - This is likely also the mechanism of action of cannabinoids for treating nausea

CB, cannabinoid receptor; CNS, central nervous system

Cannabinoids for the Treatment of Non-Cancer Pain: A Systematic Review

- Cannabinoids studied included smoked cannabis, oromucosal extracts of cannabis based medicine, nabilone, dronabinol and a novel THC analogue.
- Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain.
- **Fifteen of the eighteen trials that met the inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared with placebo** and several reported significant improvements in sleep.
- There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases.

THC, tetrahydrocannabinol
Cannabis clinical trials for chronic pain

- Limited: short length and small sample size
  - Many used THC alone or THC + CBD
- Most support for use of cannabinoids in neuropathic pain (THC+CBD).
- Increased risk of short term AEs (mostly minor) for study participants

Anti-inflammatory effects of CBD

- There are many animal models where CBD has been demonstrated to have potent anti-inflammatory effects in a variety of models (including murine collagen arthritis and carrageenan models) but it is much less clear how those anti-inflammatory effects are being mediated.

- Some evidence that anti-inflammatory effects might be occurring via CB2 (very high doses needed), adenosine receptors, arachidonic acid release (causes shift from cyclooxygenase to lipoxygenase pathway), via direct inhibition of cytokine production, or via binding to the GPR55 receptor (which has both inflammatory and nociceptive properties).

CB, cannabinoid receptor; CBD, cannabidiol; GPR55, G protein-coupled receptor 55
ZYN002 - Median Weekly Average Worst Knee Pain Score over Time - Males
ZYN002 - Median Weekly Average Worst Knee Pain Score over Time – Females
## Mechanistic Characterization of Pain

Variable degrees of any mechanism can contribute in any disease

<table>
<thead>
<tr>
<th></th>
<th>Nociceptive</th>
<th>Neuropathic</th>
<th>Centralized</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cause</strong></td>
<td>Inflammation or damage</td>
<td>Nerve damage or entrapment</td>
<td>CNS or systemic problem</td>
</tr>
<tr>
<td><strong>Clinical features</strong></td>
<td>Pain is well localized, consistent effect of activity on pain</td>
<td>Follows distribution of peripheral nerves (i.e. dermatome or stocking/glove), episodic, lancinating, numbness, tingling</td>
<td>Pain is widespread and accompanied by fatigue, sleep, memory and/or mood difficulties as well as history of previous pain elsewhere in body</td>
</tr>
<tr>
<td><strong>Screening tools</strong></td>
<td>NSAIDs, injections, surgery, ? opioids</td>
<td>PainDETECT</td>
<td>Body map or FM Survey</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>NSAIDs, injections, surgery, ? opioids</td>
<td>Local treatments aimed at nerve (surgery, injections, topical) or CNS-acting drugs</td>
<td>CNS-acting drugs, non-pharmacological therapies</td>
</tr>
<tr>
<td><strong>Classic examples</strong></td>
<td>Osteoarthritis, Autoimmune disorders, Cancer pain</td>
<td>Diabetic painful neuropathy, Post-herpetic neuralgia, Sciatica, carpal tunnel syndrome</td>
<td>Fibromyalgia, Functional GI disorders, Temporomandibular disorder, Tension headache, Interstitial cystitis, bladder pain syndrome</td>
</tr>
</tbody>
</table>

CNS, central nervous system; FM, fibromyalgia; GI, gastrointestinal

Pharmacokinetics

Route of administration influences THC pharmacokinetics, left = 5 mg i.v. injection, center = smoking 13.0 mg, or right = consuming cookie with 20 mg (Agurell et al. 1986).

Feelings of ‘high’ from different administration routes

U-Shaped Curve for cannabis effects

### Treating Based on Mechanisms

*Any combination may be present*

<table>
<thead>
<tr>
<th></th>
<th>Peripheral (nociceptive)</th>
<th>Neuropathic</th>
<th>Centralized Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDs</strong></td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Opioids</strong></td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><strong>Surgery/Injections</strong></td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><strong>Tricyclics</strong></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>SNRIs</strong></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Gabapentinoid</strong></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>CBD</strong></td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>THC</strong></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Cannabis as an opioid substitute for chronic pain?

- Cannabis as a synergist with opioids?\(^1,2\)
- State-wide analyses\(^3-5\)
  - Importance of Dispensaries in these studies (Powell et al, 2018)
- Cross-sectional\(^6-8\) and longitudinal support\(^9-11\)

Proposed marketing program for medical cannabis

Cannabis plant talking to opium producing poppy plant

We don’t suck as bad as you do
Benefits and Risks of Cannabinoids

- Definitions and Background
- Benefits of Cannabinoids
- Risks of Cannabinoids
- Role in Treating Chronic Pain
- Summary
Summary

- The endocannabinoid system is widely distributed in the human body and there is strong biological plausibility that these can be effective and safe analgesics at the right dose and in the right person.

- Cannabinoids can exert analgesic effects in the periphery (mainly anti-inflammatory) and CNS (dissociate individuals from the sensory experience of pain).

- For treatment of clinical pain with cannabinoids there is best evidence that they are effective in neuropathic and centralized pain, and little current evidence that they are effective in nociceptive/inflammatory pain states.
Pragmatic Advice for Using Cannabinoids in 2019

- Where possible use a cannabinoid or cannabinoid extract of consistent and known potency

- Start with CBD alone and then go to low dose of low THC:high CBD strain and go up slowly

- Emerging evidence of U-shaped curve

- Oral dosing better once stable dose and strain identified

- The strongest recommendation based on current benefit: risk data is for the use of cannabinoids instead of opioids for neuropathic or centralized pain states
  - Data from US suggest that legalizing cannabis in a state leads to fairly dramatic reductions in opioid overdoses\(^1\)

- Use with caution in individuals under age 25

CBD, cannabidiol; THC, tetrahydrocannabinol

How useful do you feel cannabinoids are for treating pain?

0  Worthless

10  Wonderful
Cannabis and Cannabinoids

- Definitions and Background
- Overview of Risks and Benefits of Cannabinoids
- Role in Pain Management
  - Acute vs. Chronic
- Summary
What to do when candidate for surgery discloses cannabis use?

- No need to alter typical analgesic regimen.
- Use best judgment
- No evidence for cannabinoids in surgical setting or for acute pain.
- Given length of in-patient stay, don’t really do anything for any user if patients are there for more than 1-2 days.
Summary

- Endocannabinoid system: plausibility as analgesic at right dose and in right person
- Cannabinoids can exert analgesic effects in the periphery and CNS
- For treatment of clinical pain with cannabinoids:
  - Better evidence for efficacy in chronic neuropathic pain: May be reasonable to use in place of opioids for chronic pain when all else has failed, but NOT in a surgical context.
  - No evidence for efficacy in acute/surgical pain. No clinical trial data on recovery from surgical pain
Questions?